StockMarketWire.com - HSBC today reaffirms its reduce investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 1350p (from 1225p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk